2023
Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation
Berger Y, Gadiraju M, Dhiman A, Gilliam K, Opalecky B, Chen H, Helgeson M, Eng O, Husain A, Drazer M, Kindler H, Churpek J, Turaga K. Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation. Cancer 2023, 129: 2152-2160. PMID: 37042570, DOI: 10.1002/cncr.34763.Peer-Reviewed Original ResearchConceptsBRCA1-associated protein 1Low platelet countPlatelet countGermline mutationsPeritoneal mesotheliomaPM patientsReceiver Operating CharacteristicMitotic scoreGermline testingHigher peritoneal cancer indexMitotic count scorePeritoneal cancer indexHyperthermic intraperitoneal chemotherapyReceiver operating characteristic analysisArea under the curvePhenotype of patientsCytoreductive surgeryGermline statusIntraperitoneal chemotherapyTumor burdenCancer indexSurgical characteristicsSurvival outcomesSurgical dataProspective study
2020
1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial
SHARMA A, OFSTAD A, AHMAD T, ZINMAN B, ZWIENER I, FITCHETT D, WANNER C, GEORGE J, HANTEL S, DESAI N, MENTZ R. 1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1144-p.Peer-Reviewed Original ResearchCV deathNovartis Pharmaceuticals CorporationPhenotype of patientsTreatment effectsEli LillyEMPA-REG OUTCOMERisk of outcomesType 2 diabetesAdvisory PanelBoehringer Ingelheim PharmaceuticalsBristol-Myers SquibbEMPA-REGMundipharma InternationalSanofi GenzymeCardiovascular deathCV diseaseT2D durationOlder patientsYounger patientsHeart failureAtherosclerotic diseaseSGLT2 inhibitionCox regressionDohme Corp.Patients
2019
Differential Clinical Profiles, Exercise Responses, and Outcomes Associated With Existing HFpEF Definitions
Ho J, Zern E, Wooster L, Bailey C, Cunningham T, Eisman A, Hardin K, Zampierollo G, Jarolim P, Pappagianopoulos P, Malhotra R, Nayor M, Lewis G. Differential Clinical Profiles, Exercise Responses, and Outcomes Associated With Existing HFpEF Definitions. Circulation 2019, 140: 353-365. PMID: 31132875, PMCID: PMC6684250, DOI: 10.1161/circulationaha.118.039136.Peer-Reviewed Original ResearchConceptsHeart Failure Society of AmericaEuropean Society of CardiologyClinical profileHeart failureCardiovascular outcomesComprehensive cardiopulmonary exercise testingHemodynamic profile of patientsChronic exertional dyspneaDefinitions of HFpEFExercise responseSuspected heart failureAmerican College of Cardiology/American Heart AssociationInvasive hemodynamic monitoringPhenotype of patientsIncidence of cardiovascular outcomesCardiopulmonary exercise testingProfile of patientsClinical trial criteriaSociety of CardiologyPeak oxygen uptakeConsecutive patientsHFpEF subgroupsEjection fractionExertional dyspneaPrognostic implications
2013
Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer
YING L, SU D, ZHU J, MA S, KATSAROS D, YU H. Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer. Oncology Letters 2013, 5: 1315-1320. PMID: 23599786, PMCID: PMC3629093, DOI: 10.3892/ol.2013.1144.Peer-Reviewed Original ResearchOvarian cancerSingle nucleotide polymorphismsPlatinum-based chemotherapyEpithelial ovarian cancerFresh tumor samplesPhenotype of patientsCytoreductive surgeryClinical factorsClinical outcomesPatientsStathmin geneCancerTumor samplesHuman cancersSurgeryDirect sequencingTotalLinkage disequilibrium blockAssociationPresent studyStathminNucleotide polymorphismsOutcomesDisequilibrium blockDNA samples
2011
Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure
Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure. The American Journal Of Medicine 2011, 124: 136-143. PMID: 21295193, PMCID: PMC3237399, DOI: 10.1016/j.amjmed.2010.08.017.Peer-Reviewed Original ResearchConceptsProportion of patientsHeart failureSelf-reported heart failureHeart failure populationComorbid chronic conditionsNumber of comorbiditiesNutrition Examination SurveyCare of patientsPrevalence of disabilityPhenotype of patientsComplexity of patientsMedication useRecent patientsFunctional disabilityExamination SurveyFailure populationPhysical functionPrescription medicationsPatient preferencesChronic conditionsNational HealthPatient's abilityComorbiditiesPatientsOlder individuals
1999
GATA4 haploinsufficiency in patients with interstitial deletion of chromosome region 8p23.1 and congenital heart disease
Pehlivan T, Pober B, Brueckner M, Garrett S, Slaugh R, Van Rheeden R, Wilson D, Watson M, Hing A. GATA4 haploinsufficiency in patients with interstitial deletion of chromosome region 8p23.1 and congenital heart disease. American Journal Of Medical Genetics 1999, 83: 201-206. PMID: 10096597, DOI: 10.1002/(sici)1096-8628(19990319)83:3<201::aid-ajmg11>3.0.co;2-v.Peer-Reviewed Original ResearchConceptsCardiac transcription factor genesZinc finger transcription factorHuman chromosome armsTranscription factor genesFinger transcription factorCardiac gene expressionChromosome armsTranscription factorsFactor genesGene expressionGATA4 geneInterstitial deletionGATA-4GenesLociFISH analysisSitu hybridizationDeletionHaploinsufficiencySubmicroscopic deletionRecent studiesPhenotype of patientsCellsMonosomyNormal karyotype
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply